ModernMedicine Resource Center More Topics

Video

Comprehensive care program does not cut COPD hospitalizations

A trial program of patient education/planning aimed at treating exacerbations of COPD early and reducing hospitalization rates proved ineffective.

Chronic Obstructive Pulmonary Disorder

Chronic care management of three ailments could save Medicare billions
Chronic care management of three ailments could save Medicare billionsEven modest improvements in continuity can lead to substantial savings.
Using chronic care methods to treat smoking cessation COPD
Using chronic care methods to treat smoking cessation COPDWhy taking a chronic care approach to smoking cessation is an effective way to battle the third leading cause of death in the United States
COPD risk scale could help with hospital admissions
COPD risk scale could help with hospital admissionsCanadian researchers have identified 10 clinical characteristics and developed a preliminary risk scale to help standardize admission practices for COPD patients.
FDA approves once-daily dual bronchodilator for COPD treatment
FDA approves once-daily dual bronchodilator for COPD treatmentThose treated with Umeclidinium and vilanterol inhalation powder showed improved lung function.
New once-daily COPD Rx available in U.S. pharmacies
New once-daily COPD Rx available in U.S. pharmaciesFluticasone furoate and vilanterol inhalation powder (Breo Ellipta, GlaxoSmithKline and Theravance) once-daily for chronic obstructive pulmonary disease, is now available to pharmacies throughout the United States.
Statins offer 30% lower risk of COPD exacerbation
Statins offer 30% lower risk of COPD exacerbationA new retrospective case-control study among patients with chronic obstructive pulmonary disease found a 30% decreased risk of COPD exacerbation with any statin use.
Breo Ellipta for long-term treatment of COPD gets FDA nod
Breo Ellipta for long-term treatment of COPD gets FDA nodFluticasone furoate and vilanterol inhalation powder combo is a long-term, once-daily maintenance treatment for COPD
COPD: Exploring the value of care
COPD: Exploring the value of careThe latest installment in Medical Economics' Business of Health series examines the societal costs of chronic obstructive pulmonary disease and how physicians can address them in their practices.
Reduced rate of COPD-related hospitalizations seen with long-term ICS/LABA combination therapy
Reduced rate of COPD-related hospitalizations seen with long-term ICS/LABA combination therapyLong-term treatment with fixed-combination budesonide/formoterol (Symbicort Turbuhaler, AstraZeneca) was associated with fewer healthcare utilization-defined exacerbations and hospitalizations than fluticasone/salmeterol in patients with moderate and severe chronic obstructive pulmonary disease (COPD), according to a study published online in the Journal of Internal Medicine.
FDA approves aclidinium bromide inhalation powder to treat COPD
FDA approves aclidinium bromide inhalation powder to treat COPDFDA has approved aclidinium bromide inhalation powder (Tudorza Pressair, Forest Pharmaceuticals) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.